LONDON, Aug 3 (Reuters) - Sanofi-Aventis (SASY.PA) chief Chris Viehbacher should avoid paying much more than about $70 per share, or a total of $19 billion, to land U.S. biotech group Genzyme (GENZ.O), shareholders in the French group say.
LONDON, Aug 3 (Reuters) - Sanofi-Aventis (SASY.PA) chief Chris Viehbacher should avoid paying much more than about $70 per share, or a total of $19 billion, to land U.S. biotech group Genzyme (GENZ.O), shareholders in the French group say.
